3 gorgeous stocks that could translate or more by 2030

Does a 100% return in less than seven years sound good? Most investors would probably say so. But which stocks are suitable for such a return?

Three contributors to the Motley Fool think they've found a gorgeous stock that could translate double or more by 2030. Here are their choicesCRISPR Therapeutics (NASDAQ Resonance Symbol: CRSP),come with a giftDispensary (New York Stock Exchange Stock Code: LLY(math.) andViking Therapeutics (NASDAQ: VKTX)The reason.

CRISPR Therapeutics Has Huge Long-Term Promotional Potential

David Jagielski (CRISPR Therapeutics):CRISPR Therapeutics is a promising stock with plenty of room for future growth. Its current market capitalization is about $5.1 billion, but it's easy to see how it could soar above $10 billion by the start of the next decade.

The healthcare company is in the early stages of development, as the FDA recently approved the development of a name with its development partner, Firma.VertexA gene therapy developed by the company; it is the first treatment in the CRISPR Therapeutics product portfolio to be approved. The U.S. Food and Drug Administration (FDA) approved the treatment's labeling.TwoCasgevy is indicated for the treatment of two blood disorders, transfusion-dependent beta-thalassemia and sickle cell disease. The fact that this treatment can functionally cure both diseases is transformative for patients with both diseases, so treatment experts say it is cost-effective, even at a price of more than $2 million per treatment.

In my view, CRISPR Therapeutics will double in valuation by 2030. One is through pure organic growth. While the company will share Casgevy's profits with Vertex, it has other gene therapies in development. However, the price of Casgevy is so high that the profits from the treatment alone could be very significant and could provide a path to profitability (last year the company had a net loss of $153.6 million). Analysts believe Casgevy could generate nearly $4 billion in annual revenue at its peak.

Another route is acquisition. Many healthcare companies are increasingly interested in gene therapy, and CRISPR Therapeutics could be a potential acquisition target due to its growing reputation in the industry. The company has no long-term debt on its books and has over $2 billion in cash, which could make it a sweet deal for a potential acquirer. If CRISPR Therapeutics' financials remain this strong, it could be a company to watch.

The future looks bright. By 2030, CRISPR Therapeutics is a stock that certainly has the potential to grow.

The first trillion-dollar healthcare stock?

Prosper Junior Bakiny (Eli Lilly):In the stock market, modes matter: small companies often have more room for upward mobility than large ones. So picking a big company like Eli Lilly, with a market capitalization of $725 billion, to translate over the next six years or so may not be the most obvious choice. But it's still a good choice. Lilly has been going strong lately, with a number of major breakthroughs in clinical and regulatory medicine. It remains one of the undisputed leaders in the huge diabetes drug market.

The drug company has also established itself in the fast-growing weight-loss sector, thanks to Zepbound, a drug that got the green light late last year, and it won't be the only one: Lilly's portfolio of carbs is highly diversified, with exciting treatments and drug candidates in the fields of oncology, immunology, and neuroscience.

Lilly is currently awaiting approval of another potential blockbuster, donanemab, for Alzheimer's disease (AD). This area is known as the graveyard of research drugs, as most attempts to develop new Alzheimer's disease treatments have been unsuccessful. While Lilly still has a key regulatory hurdle to clear before it can get its drug approved, the outlook for the drug giant is promising.

However, Lilly's prospects do not depend on a single approval or rejection. Regardless of what happens with donanibizumab, the company is poised for excellent growth through 2030. The drugmaker could well become the first healthcare stock to top the $1 trillion mark, and continue to grow long afterward. As small as it is, Lilly could double its share price or more over the next six years.

A Small Biotech Company That Should Have Grown Bigger

Keith Speights (Virgin Therapy Inc.)Viking Therapeutics: You can look at Viking Therapeutics in several ways. Some might consider it ridiculously expensive for a clinical biotech company with a market capitalization of nearly $8 billion. Others may see Viking as a rising star with the potential to grow even bigger. I'm firmly in the second camp.

Shares of Viking have been on a tear this year, thanks to two positive Koon updates: In late February, the company announced the results of a Phase 2 study of its obesity drug, VK2735 injection. A month later, Viking reported optimistic data from a Phase 1 study evaluating the drug's oral formulation.

Goldman SachsThe global obesity drug market is predicted to reach $100 billion by 2030. Assuming there are no problems with VK2735's post-testing, Viking appears to be in a position to take a significant share of this market with VK2735.

The company also has another potential big winner - VK2809. viking expects to announce histological results from a Phase 2b study of the drug for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis in the first half of 2024. The biotech reported positive first-line results from the study in the second quarter of 2023.

NASH, also known as Metabolic Dysfunction Associated Steatohepatitis (MASH), is another huge market opportunity for Viking. Estimates of the growth of the NASH/MASH market vary, but some analysts believe the market could reach $100 billion by 2030.

With these two promising candidates, targeting two huge markets, I think Viking's stock could be on the move by the end of the decade. I also suspect that the company will become a major acquisition target in the near future.

Should you invest $1,000 in CRISPR Therapeutics now?

Consider this before buying shares of CRISPR Therapeutics:

Motley Fool Stock AdvisorA team of analysts has just named what they think is the best name for investors to buy right now.10Only ...... and not CRISPR Therapeutics. The 10 stocks that made the list could generate huge returns in the coming years.

Stock AdvisorIt provides investors with an easy-to-understand blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. Since 2002, StockAdvisorThe service has more than doubled the return on the S&P 500 Index.

View 10 stocks only

*Stock Advisory Rates as of April 8, 2024

David Jagielski does not own any of the stocks mentioned above. keith Speights has a position in Vertex Pharmaceuticals. prosper Junior Bakiny owns shares of Vertex Pharmaceuticals. the Motley Fool holds a recommendation in CRISPR Therapeutics, Goldman Sachs Group and Vertex Pharmaceuticals. the Motley Fool has a disclosure policy. CRISPR Therapeutics, Goldman Sachs Group, and Vertex Pharmaceuticals.The Motley Fool has a disclosure policy.

3 Gorgeous Stocks That Could Double or More by 2030 was originally published by The Motley Fool.